10-Q quarterly report · filed Nov 5, 2026

Rezolute, Inc. (RZLT) Q3 2026 10-Q Quarterly Report

Short answer

Rezolute, Inc. (RZLT) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$18M
−1.9% YoY
EPS (diluted)
−$0.18
+0.0% YoY

Source: XBRL data from the Rezolute, Inc. (RZLT) Q3 2026 10-Q on SEC EDGAR. USD.

Rezolute, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0 for Q3 2026, unchanged from $0 in Q3 2025
  • Net loss $18.5M vs $18.2M YoY, no operating margin disclosed
  • Tumor HI upLIFT: 7 of first 8 participants met responder criteria, all discontinued intravenous glucose
  • Cash and investments $90.0M at September 30, 2026, sufficient for at least 12 months
  • Operating cash outflow $18.8M vs $17.4M YoY, with $15.8M investing cash inflow

Risk Factors

  • Newly added regulatory risk: FDA pre-BLA recommendation may not support ersodetug approval for congenital HI
  • Clinical-development risk: FDA could require another sunRIZE-like study, delaying BLA submission and increasing costs
  • Newly added trial risk: Phase 3 upLIFT topline results expected December 2026 may fail to meet endpoints for tumor HI approval
  • Carried-forward risks: 2026 Form 10-K risk factors otherwise unchanged materially

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Rezolute, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.